SLC16A1 and breast cancer: Since the function of the Wnt signaling pathway is important in BC carcinogenesis and development (31, 32), and WIF1 is an antagonist of the Wnt signaling pathway (33), our findings revealed a therapeutic implication of the SLC16A1-AS1/miR-552-5p/WIF1 pathway in BC patients.